Norman B. Gaylis


Norman B. Gaylis is recognized as one of the country’s leaders in the field of arthritis and rheumatic diseases. He is board-certified in Internal Medicine and Rheumatology and has been a practicing Rheumatologist in the greater Miami area for more than 35 years. Dr. Gaylis was born in Johannesburg, South Africa and completed his training as a rheumatologist at the University of Miami where he served on the clinical faculty for many years. Dr. Gaylis has presented numerous scientific papers and has conducted medical meetings around the United States and internationally. He is the author of multiple peer reviewed articles, in particular on the subjects of rheumatoid arthritis, magnetic resonance imaging in rheumatology and other rheumatic disorders.

In addition to his clinical practice, he was the past Medical Director for the Rheumatology division at Cardinal Health and is a speaker and consultant for numerous pharmaceutical companies. Dr. Gaylis is the Medical Director of AARDS Research, Inc., a clinical research organization specializing in clinical research trials for autoimmune diseases and the Medial Director of Infusion and Immunotherapy Center of South Florida (IIC.) He has been a Principal Investigator in over 150 clinical trials for new pharmaceutical products for the treatment of Rheumatoid Arthritis, Osteoarthritis, Osteoporosis, Systemic Lupus, Lupus Nephritis, Gout, and Sjogren’s syndrome.

The recipient of many awards and honors, Dr. Gaylis is an active member of the American College of Rheumatology (ACR) and is currently serving as a Board Member. Dr. Gaylis is a 2017 recipient of the Master of the ACR Designation. Recognition as a Master is one of the highest honors that the College bestows on its distinguished members.

He is a past Board member of the Rheumatology Research Foundation. As part of his commitment to clinical research, he has recently established an endowment (Norman B Gaylis, MD Research Award for Rheumatologists in Community Practice) for the Rheumatology Research Foundation to award annually for the exclusive support of research by rheumatologists in clinical practice. He strongly believes in the benefits of clinical research breaking the ground for new treatments and the viability of rheumatologists in the future of healthcare.

He is one of the founders and is a Past President of the International Society for Musculoskeletal Imaging in Rheumatology (ISEMIR). He is also a past president of the Florida Society of Rheumatology.

He has been featured in the Wall Street Journal, on multiple television news shows, and for many years was also the host of HEALTH TALK, a medical talk show on the radio in South Florida. He is also on the Editorial Board of Rheumatology News for which he has contributed numerous articles.

Medical School:

University of Witwatersrand
Johannesburg, South Africa
(6 year program) 1967 – 1973


Clinical: University of Witwatersrand Rotating Internship 1974 – Surgery, Orthopedics, Internal Medicine. Medical Registrar, Johannesburg General Hospital 1975 – 6 months

Pathology Registrar at South African Institute for Medical Research 1975 – 12 months.

United Kingdom: Medical House Officer at Guys Hospital and Harley Street Clinic 1976 – 6 months.

United States:

Internal Medicine Residency at Mt. Sinai Medical Center, Miami Beach, Florida
Residency, June 30-1976 – June 30, 1977
Chief Medical Resident, July 1, 1978 – June 30, 1979


Department of Rheumatology, University of Miami Medical School, Miami, Florida,
July 1, 1979 – June 30, 1981

Current Clinical Practice and Divisions of Practice:

Arthritis and Rheumatic Disease Specialties
Aventura, FL, 33180. Private Practice of Rheumatology, Medical Director Clinical Laboratory Norman B Gaylis, MD, June 30, 1981 – Present

AARDS Research, Inc., Arthritis & Rheumatic Disease Specialties Research Medical Director and Primary Investigator April 2010-present

Infusion and Immunotherapy Center of South Florida (IIC), Medical Director September,2014-present

Business Experience:

Medical Director Rheumatology, Cardinal Health Specialty Solutions 2010-2013

Chief Operating Officer of Rheumatology, Continucare Corporation 1996 – 1999

Chief Operating Officer of Rheumatology Physicians Practice Division, Sheridan Healthcare 1992

Founder and Director of Miami Arthritis Center 1985-1999

Academic and Educational Appointments:
  • Rheumatology Medical Director International Physicians Network 2020 to present
  • Scientific Board of CytoDyn Inc. 2020-present
  • Scientific Board Inmedix, Inc. 2020-present
  • Board of Directors American College of Rheumatology (ACR) 2019- present
  • Board of Directors Rheumatology Research Foundation 2018-2019
  • Board of Directors ICAMRL 2012-2016
  • Editorial Board, Rheumatology News 2008-Present
  • President of International Society for Musculoskeletal Imaging in Rheumatology (ISEMIR) 2008-2010
  • American College of Rheumatology Research and Education Foundation 2006-2010
  • President of International Society for Musculoskeletal Imaging in Rheumatology(ISEMIR) 2008-2010
  • Program Chair for International Society for Musculoskeletal Imaging in Rheumatology(ISEMIR) 2007-2010
  • Clinical Associate Professor of Medicine Department of Rheumatology University of Miami, 1992 – 2002
  • President Florida Society of Rheumatology, 1992, 1994
  • Physician Ad. Committee Medicare BCBS-Florida 1992 – 1994
  • Program Chairman – Florida Society of Rheumatology, 1989 – 1991
  • Executive Member of Committee of Rheumatologic
    Care, American College of Rheumatology, 1986-
  • Member of Marketing Committee of American College of Rheumatology, 1987 – 1989
  • Florida Representative on American College of Rheumatology Committee of Rheumatologic Care1985, 1986 and 1987
  • Fellow American College of Physicians, 1984

American Board of Internal Medicine 1979 No.73208.

American Board of Rheumatology November 1983 ME31090.

ECFMG 1972 No. 20098274.

Flex 1978 No. 192529.

Publications and Presentations:

Switching to Biosimilar SDZ-ADL in Patients with Moderate-to-Severe Active Rheumatoid Arthritis: 48-Week Efficacy, Safety and Immunogenicity Results From the Phase III, Randomized, Double-Blind ADMYRA Study, BioDrugs 2020 Oct 29 doi: 10.1007/s40259-020-00447-6

The Financial Impact of Covid-19 on Rheumatology Practices The Rheumatologist Sep 2020

Safety and efficacy of neurostimulation with a miniaturized vagus nerve stimulation device in patients with multidrug-refractory rheumatoid arthritis: a two-stage multicentre, randomized pilot study. Lancet, July 2020

A Randomized, Double-Blind, Parallel-Group, Multicenter Study to Compare the Efficacy, Safety and Immunogenicity of a Proposed Adalimumab Biosimilar (GP2017) with Reference Adalimumab in Patients with Moderate-to-Severe Active Rheumatoid Arthritis ACR 2018

Clinical and Structural Responses of Patients with Active Rheumatoid Arthritis (RA) Using Step-Up Dosing of Tofacitinib in a Treat To Target Approach. ACR/AHRP, San Diego, CA 2017

Patient Perspectives on Intravenous Biologics for Rheumatologic Disease

Patient-Reported Outcome Assessment of Inflammatory Arthritis Patient Experience With Intravenously Administered Biologic Therapy

Patient Perspectives on Intravenous Biologics for Rheumatologic Disease

PRO Assessment of Rheumatoid Arthritis Patients Experience With IV Administered Biologic Therapy. ACR/AHRP San Francisco, CA 2015.

Interim Analysis: The Effect of Adrenocorticotrophin Gel (HP Acthar Gel) in Combination with Methotrexate in Newly Diagnosed Rheumatoid Arthritis Patients from a Clinical and Structural Perspective. ACR/AHRP, San Francisco, CA 2015.

Covergent Validity of New Disease Assessment Instruments in Systemic Lupus Erythematosus in Relation to SLEDAI-2K. ACR/AHRP, San Francisco, CA 2015.

Safety of Infusing Rituximab. BMC Musculoskeletal Disorders, 2014

The Value of Magnetic Resonance Imaging. Journal of Clinical Rheumatology Volume 00, Number 00, June 2014

IM 101-006 BMS Assessment of Structural Benefits Of Abatacept as Measured by Low Field MRI n Patients with Rheumatoid Arthritis Who Have failed Prior TNF Therapy and Correlated with Clinical Outcomes as Measured by an Automated DAS 28 Scoring System 2010-2013 27 patients

Results from the RATE-RA Study: A Multicenter, Single-Arm Study to Evaluate the Safety of Administering Rituximab at a More Rapid Infusion Rate in Patients with Rheumatoid Arthritis. ACR/AHRP San Diego, October 2013.

Magnetic Resonance Imaging May Be Helpful in Predicting Long Term Efficacy of Certolizumab Pegol in Patients with Active Rheumatoid Arthritis.
EULAR, Madrid, Spain June 2013

Results from the Rate – RA Study. A Multicenter Open-Label, Single-Arm Study to Evaluate the Safety of Administering Rituximab at a More Rapid Infusion Rate in Patients with Rheumatoid Arthritis.
EULAR, Madrid, Spain June 2013

Five-Year Safety and Efficacy of Golimumab in Patients with Active Rheumatoid Arthritis Despite Previous Anti-Tumor Necrosis Factor Therapy: Final Study Results of the Phase 3, Randomized, Placebo-Controlled Go-After Trial
EULAR, Madrid, Spain June 2013

Key Changes in Health Care. Rheumatology Advisory Board Meeting, March 2013

5th Annual Int’l Society Musculoskeletal Imaging. Volume 42, Number 4, February 2013

Evaluating Joint-Space Narrowing and Cartilage Loss in Rheumatoid Arthritis by Using MRI. Arthritis Research Therapy, May 2012.

Golimumab in patients with active rheumatoid arthritis who have previous experience with tumour necrosis factor inhibitors: results of a long-term extension of the randomized, double-blind, placebo-controlled GO-AFTER study through week 160. Ann Rheum Disease January 2012

Long-term Follow-Up of an HIV infected patient with Reactive Arthritis Treated with Infliximab. Journal of Clinical Rheumatology April 2012.

Magnetic Resonance Imaging in Rheumatoid Arthritis Clinical Trials: Emerging Patterns Based on Recent Experience. The Journal of Rheumatology, October 2011.

Golimumab Administered Subcutaneously Every Four Weeks in Patients with Active Rheumatoid Arthritis Who Were Previously Treated with Anti-TNF Agent(s): Efficacy Results of the Randomized Double-Blind, Placebo-Controlled, Go-After Study Through Week 160 EULAR, London, England May 2011

Comparison of 1.5T Whole-Body MRI and 0.2T Extremity MRI for Monitoring Rheumatoid Arthritis in a Multi-Site Clinical Trial (IMPRESS) EULAR, London, England, May 2011

Both High and Low Field MRI Correlate With Clinical Assessments and Biomarkers in Patients With Active Moderate to Severe Rheumatoid Arthritis EULAR , London, England 2011

Computer Assisted Patient Reported (PR) Versus Physician Generated (PG) Joint Count (JC) and DAS28
Scores for Rheumatoid Arthritis (RA) Patients, ACR/ACHP Scientific Meeting, Atlanta, GA, November 2010

Golimumab in Rheumatoid Arthritis Patients Previously Treated with Anti-TNF Alpha Agents: 2 Year Results from Go-After Study, EULAR, Rome, Italy, June 2010

Monitoring Joint-Space Narrowing in Rheumatoid Arthritis with 1.5T Whole Body MRI and 0.2T Extremity MRI in a Multi-Site Clinical Trial: IMPRESS, EULAR, Rome, Italy, June 2010

MRI Findings Correlate with Clinical Assessments and Biomarkers in Patients with Active Moderate or Severe Rheumatoid Arthritis, EULAR, Rome, Italy, June 2010

Retreatment with Rituximab Based on a Treatment to Target Approach Provides Better Disease Control than Treatment as Needed in Patients with RA, EULAR, Rome, Italy, June 2010

A Pilot Study of 10 Patients Measuring High and Low Field MRI Findings and Clinical Outcomes on Patients with Rheumatoid Arthritis Treated with Abatacept, EULAR, Rome, Italy June 2010

Efficacy and Safety of Retreatment in Patients with Rheumatoid Arthritis with Previous Inadequate Response to Tumor Necrosis Factor inhibitors: Results from the SUNRISE Trial. Journal of Rheumatology, 01 March 2010.

Discriminative Power of Different Combinations of Bones and Joints for Assessing Change in Rheumatoid Arthritis with MRI: Results Based on Pooled Data from Four Multisite Clinical trials. ACR/ACHP, Atlanta, GA 2010

Retreatment with Rituximab (RTX) Based On a Treatment to Target (TT) Approach Provides Better Disease Control Than Treatment as Needed (PRN) in Patients (pts) with Rheumatoid Arthritis (RA), ACR Annual Meeting, Philadelphia, PA October 2009

Golimumab in Patients with Active Rheumatoid Arthritis After Treatment with Tumour Necrosis Factor α Inhibitors (GO-AFTER Study); A Multicentre, October 2009

Strategies For Improving Treatment Outcomes, October 2009

Randomised, Double-Blind, Placebo-Controlled, Phase III Trial. The Lancet, June 2009.

In-Office Magnetic Resonance Imaging to Monitor Responses to Therapy in Rheumatoid Arthritis, Rheumatology International, Volume 30, No. 2, April 2009.

Golimumab in Rheumatoid Arthritis Patients Previously Treated with Anti-TNFα Agents (GO-AFTER Study): Week 52 Results, ACR Annual Meeting, Philadelphia, PA 2009

Evaluating Osteitis in Rheumatoid Arthritis with Gadolinium-enhanced MRI. ACR, San Francisco, CA 2008

Golimumab, a Human Anti-TNFα Monoclonal Antibody, Injected Every 4 Weeks: Efficacy & Safety in RA Patients Previously Treated with Anti-TNFα Agents (GO-AFTER Study). ACR, San Francisco, CA 2008

Adding Extremity MRI to Your Practice. Rheumatology News. Volume 8, Number 8, August 2008

Efficacy, Safety, And Dose Frequency Of Retreatment With Rituximab in RA: Results From A Randomized Controlled Trial (SUNRISE) ACR, San Franciso, CA 2008

Rheumatology And Infusion Therapy: Practice and Treatment Choices in the New Era, A Series of

Interactive CME Discussions The Foundation for Better Health Care (FBHC), 2007

Image of the Month. Rheumatology News, Volume 6, No.12, December 2007

Image of the Month. Rheumatology News, Volume 6, No. 10., October 2007

Extremity Imaging Improves RA Care. Rheumatology News, Volume 6, No. 9., September 2007

Comparison of In-office MRI Versus Conventional Radiography in Detecting Changes in Erosions After One Year of Infliximab Therapy in Patients With Rheumatoid Arthritis, Modern Rheumatology, the Journal of the Japan College of Rheumatology Mod Rheumatol (2007) 17:273-278, DOI 10.1007/s10165-007-0591-x

Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the opposite study, Ann Rheum Dis 2007;doi:10.1136/ard.2006.068304

Inflammatory, B Cartilage markers correlated with Efficacy, EULAR, Amsterdam, Netherlands 2006

Open, Randomized Study of Rheumatoid Arthritis Patients switched from Etanercept: Changes in Serum

Adalimumab Efficacy in Psoriatic Arthritis Patients Oligoarticular Arthritis: Sub analysis of Adept, EULAR, Amsterdam, Netherlands 2006

Comparison of Two Different In-Office 0.2T Magnetic Imaging Systems and Standard Radiographs in an Outpatient Rheumatoid Arthritis Patient Population, EULAR, Amsterdam, Netherlands 2006

Infliximab Provides Additional Clinical and Radiographic Benefits in RA Patients Who Have an Inadequate Response to Etanercept, EULAR, Vienna, Austria 2005

Changes in Erosive Status Detected on In-Office MRI after One Year Follow-up of Rheumatoid Arthritis Patients on Infliximab Therapy, EULAR, Vienna, Austria 2005

Comparison of In-Office MRI Versus Conventional Radiography In Detecting Changes In Erosions after One Year Follow-up Exams in Rheumatoid Arthritis Patients on Infliximab Therapy, EULAR, Vienna, Austria 2005

Effects of Cycloxygenase-2 (COX-2) Selective Inhibitor Non-steroidal Anti-Inflammatory Agents on Bone Mineral Density, ISCD, New Orleans, 2005

Rheumatoid Arthritis the Present and the Future Pacifico Yokohama, Japan 2005

JCR Congress of Rheumatology, Guest Speaker

Discontinuation of Corticosteroids Following Initiation of Infliximab in Patients with Refractory Rheumatoid Arthritis, EULAR, Berlin, Germany, 2004

Use of In-office MRI in the Evaluation of Patients With Rheumatoid Arthritis in Infliximab Therapy, EULAR, Berlin, Germany 2004

Infliximab in the Treatment of an HIV Positive Patient with Reiter’s Syndrome – Journal of Rheumatology 2003; 30-2, Pages 407-411

The Many Facets of Rheumatoid Disease . A.L.M. Plus, Page 10 Newsletter Library, March 1988

Initial Evaluation of the Arthritis Patient Postgraduate Medicine, Vol. 80, No. 50, October, 1986

An Evaluation Tool for the Diagnosis and Management of Arthritis Disorders – The Continuum of Arthritis: A Complete Approach to Treatment, 1985

The Select Value of Computer Assisted Tomography of the Brain in Cerebritis due to S.L.E., J. Rheumatol, 9:6 1982

Pulmonary Infiltration in S.L.E. – Various Causes. Workshops in Rheumatology, Vol. 3, No. 5, 1982

Uncommon Causes of Septic Arthritis in S.L.E. – Rheumatology News, March, 1981

Arthritis in S.L.E., Question and Answer Format Workshops in Rheumatology, Vol. 2, No. 2, 1981

Bacterial Monarthritis Due to Neisseria Meningitides in S.L.E.,J. Rheumatol, 8:1 1981

Ongoing Study of Salivation Induced with Salivator in Sjogren’s Patients with Xerostomia – American Rheumatism Association National Meeting, Washington, D.C

Dermatomyositis and Atypical Mycobacteria Terrae Presenting as a Class Tenosynovitis, American Rheumatism Association December 1985, Savannah, GA

Induction of Saliva in Patients with Xerostomia, Secondary to Sjogren’s Syndrome, with Aide of a Salivator. Southeastern American Rheumatism Association.December 1985, Savannah, GA.

Comparison of Oral and Intramuscular Low Dose Methotrexate, International League of Rheumatism Meeting, May 1985, Sydney, Australia

Low Dose Pulse Methotrexate in Rheumatoid Arthritis, A Clinical Overview of 65. American Rheumatism Association Southeastern Meeting, 1984

Best Paper Presented – Thieves Market

S.L.E. and Immunosuppressive Therapy Complicated by StrongyloidesStercoralis, American Rheumatism Association Meeting, June 1981

Selective Values of CAT of the Brain in Cerebritis Due to S.L.E., American Rheumatology Meeting, June 1981 and International Rheumatology Meeting, June 1981.

Septic Arthritis in S.L.E., American Rheumatism Association, Southeastern Meeting, November 1980

Press Releases: IST/ISR Primary Investigator Clinical Research:
Clinical Research Trials:
  1. Crescendo VIVID RA 2020-ongoing
  2. Vorso – Vorso PROTECT System 2020-ongoing
  3. Eli-Lilly SLE 2020-ongoing
  4. AbbVie AS Upadacitinib 2020-ongoing
  5. GKS RA Contrast 2020-ongoing
  6. BMS SLE JAK 2020-ongoing
  7. SetPoint- RA-vagal nerve implant device- 2018-ongoing
  8. BMS-SLE-JAK 2018-ongoing
  9. Janssen -SLE ustekinumab-2018 -2020
  10. AbbVie – PsA- ABT494- 2018-ongoing
  11. Novartis, CHOICE PsA secukinumab 2016- ongoing
  12. Amgen RA Biosimilar/Infliximab 2016-ongoing
  13. Ablynx SLE ALX-0061 2016-ongoing
  14. Sandoz RA GP2017/Humira 2016-ongoing
  15. Amgen RA Biosimilar/Rituximab 2016-ongoing
  16. Pfizer OA 2016-ongoing
  17. Eli Lilly AS 2016-ongoing
  18. Gilead RA Filgotinib 2016-ongoing
  19. Novartis AS secukinumab 2015-ongoing
  20. Astra Zeneca SLE 2-15-ongoing
  21. Amgen PsA 2015- ongoing
  22. Pfizer RA Tofacitinib/MTX/Adalimumab 2014-ongoing
  23. Pfizer- RA- Infliximab-Pfizer 2014 –ongoing
  24. Amgen PsA Enbrel 2014-ongoing
  25. Roche- RA 2013- ongoing
  26. Sanofi RA-2013 -ongoing
  27. Novartis PsA- 2013- ongoing
  28. Vertex RA 2012-2013
  29. Novartis RA 2011-2014
  30. Janssen RA IL6 (no MTX)2012-ongoing
  31. Janssen RA IL6 (MTX) 2013-ongoing
  32. Genentech SLE 2010-2012
  33. GSK (BLISS) SLE 2012-ongoing
  34. UCB SLE 2012-ongoing
  35. Pfizer (oral tablet) RA 2010-ongoing
  36. BMS RA Abatacept SC RA 2010-2014
  37. Centocor RA Go Save 2010-2013
  38. UCB certolizumab AS 2010-2013
  39. UCB certolizumab PsA 2010-ongoing
  40. Roche AS-2010-2012
  41. UCB RA-2010-2012
  42. Eli Lilly RA multiple trials 2011-2013
  43. Celgene PsA 2010-2012
  44. Cephalon SLE 2010-2012
  45. Eli Lilly SLE 2011-ongoing
  46. Takeda Gout with Cardiac Risk assessment 2011- 2012
  47. Rigel/AZ RA 2008-2012
  48. Human Genome 2008 Belimumab Lupus ongoing
  49. Incyte RA (oral tablet) 2009-2010
  50. BMS Abatacept RA 2008-2010
  51. Roche MRA RA 2008-2012
  52. BMS Abatacept SC, 2008-2010
  53. UCB Certolizumab RA 2008-2011
  54. Genentech- Rituxan Lupus 2007-2010
  55. Genentech 2007 Ocrelizumab RA 2010
  56. Centocor RA IV Golimumab 2007-2009
  57. Human Genome 2007 Belimumab Lupus
  58. TAP Febuxostat Gout 2007-2008
  59. Amgen Etanercept RA 2007-2008
  60. Amgen AMG 108 RA 2007
  61. Biogen BG9924 RA 2007-2009
  62. Abbott-RA Humira/MTX MRI 2007-2010
  63. Merrimack-RA alpha feta protein 2007-2008
  64. Centocor-2006-2012 RA Golimumab
  65. Savient-2006-2010 Gout Uricase Agent
  66. Novartis- OA Hip 2005-2006
  67. Celltech/UCB- CDP-870 RA 2005-2011
  68. Roche- RA-2005-2011 MRA
  69. Genentech- RA- Rituxan 2005-2012
  70. GSK- OA 2005
  71. DOV- Chronic Back Pain 2005
  72. BMS- Abatacept- Open label RA 2010
  73. Human Genome- 2005 Belimumab Lupus 2010
  74. Centocor- 2005-2012 Golimumab PsA
  75. Immunomedics- 2005-2005 SLE
  76. Human Genome Sciences – Belimumab RheumatoidArthritis 2004-2006
  77. Bristol-Myers-Squibb RA 2004-2011
  78. Sepracor –RA Insomnia 2004-2005
  79. Amgen Rheumatoid Arthritis 2003
  80. Pharmacia Rheumatoid Arthritis 2003
  81. MedImmune Rheumatoid Arthritis 2003-2005
  82. Genentech Rheumatoid Arthritis 2003-2009
  83. Human Genome Sciences Lupus Erythematosus 2003-2008
  84. TAP Gout Febuxostat 2003-2005
  85. Sanofi Shoulder Pain- 2003-2004
  86. Lilly Forteo-2003-2010
  87. Merck Cox 2 Safety 2002-2003
  88. Pharmacia Cox 2 Safety 2002
  89. Amgen Anakinra post market 2002-2003
  90. TAP Gout 2002-2004
  91. Alexion – Rheumatoid Arthritis-anti TNF 2002-2004
  92. Celecoxib – Searle – Osteoarthritis/Rheumatoid Arthritis 2000
  93. Cox-2 – Merck – Osteoarthritis Hip/Knee – 1999 – 2000
  94. Trocade – Roche – Rheumatoid Arthritis – 1999 – 2001
  95. Rofecoxib – Merck – Rheumatoid Arthritis – 1999-2000
  96. Celecoxib – Searle – Osteoarthritis/Rheumatoid Arthritis – 2000
  97. P & G – Osteoarthritis – 1999 – 2003
  98. Valdecoxib – Searle Osteoarthritis/Rheumatoid Arthritis 2000 – 2003
  99. Cox-2 – Merck – Osteoarthritis Knee – 1999 – 2000
  100. Infliximab – Centocor- Rheumatoid Arthritis Post Market 1999-2000
  101. Abbott Humira Rheumatoid Arthritis – 2000 – Ongoing
  102. Celecoxib – Searle – Osteoarthritis – 1998
  103. Celecoxib – Searle – Osteoarthritis Hip – 1997
  104. Celecoxib – Searle – Osteoarthritis Knee – 1997
  105. Celecoxib – Searle – Rheumatoid Arthritis – 1997
  106. Dry Mouth – Pharmaco – 1997
  107. Tenidap – Rheumatoid Arthritis – Pfizer – 1995-1997
  108. Salagen – Sjogren’s Syndrome – 1995 – 1996
  109. Risedronate – Osteoporosis – Proctor Gamble – 1993 – 1999
  110. Benoxaprofen – Rheumatoid Arthritis – Eli Lilly – 1979
  111. Ridaura – Methotrexate – Smith Kline Beecham – 1988
  112. Nabumetone – Smith Kline Beecham – 1991
  113. Salitron Salivary Gland Stimulation Biosonic Inc. – 1988 – 1992 Sjogren’s Study
  114. Therafectin – Quintiles – 1987
  115. Diclofenac NA – Ciba Geigy – 1984 – 1987
  116. Ridaura – Methotrexate – Smith Kline Beecham – 1980 – 1981

American Medical Association
American College of Physicians
American College of Rheumatology
International Society for Musculoskeletal Imaging in Rheumatology (ISEMIR)
Florida Society of Rheumatology
Florida Medical Association

OFFICE ADDRESS: 21097 NE 27th Court
Suite 200
Aventura, Florida 33180
Phone : (305) 652-6676
Facsimile : (305) 932-6335
E-mail :

Copyright © 2021 Arthritis & Rheumatic Disease Specialties | Nondiscrimination | Privacy Practices | Accessibility | Limited English Assistance Services
Join Our Newsletter

Dr. Norman Gaylis and his practice have been serving the surrounding community since 1982 and have built a reputation both nationally and internationally. Our physicians are board certified and are specialists in treating musculoskeletal disorders.

Join our email list to get updates from our office.